aBACTER - TU Munich
Innovation & Business Idea
Approved antibiotics rapidly induce resistance in bacteria and show only limited treatment options in case of biofilms and persister cells. There is an urgent need for structurally novel antibacterial compounds with new modes of action lacking resistance development. aBACTER compounds address these limitations by their unique antibacterial profile and an already established in vivo PoC study completes the feasibility of our business concept.
Customers / Target Market
aBACTER antibiotics aim to treat severe bacterial infections which currently lack adequate treatment options. Customers of novel antibiotics are big pharma companies, as well as smaller biotech and SMEs. aBACTER’s unique antibacterial profile enables the treatment of severe infections such as endocarditis with estimated annual sales of around $600 M in year five after FDA approval.
The FDA-approved antibiotics daptomycin and linezolid are the main competitors. Daptomycin used to be and still is the standard therapeutic for endocarditis, however, resistance development against daptomycin can be more frequently observed. Similar to linezolid, aBACTER antibiotics can be administered orally, an advantage compared to the competitor daptomycin.
Intellectual Property Status
aBACTER filed a patent in May 2016 (WO2017207556) and currently the nationalization of the patent application is running in EU, USA, Canada, Japan, Singapore and China.
Development Status & Future Steps
aBACTER currently drives the preclinical development of our novel antibiotics. Within the last 12 months we worked on the synthesis of a compound library comprising about 350 substances. Their antibacterial profile was determined by different in vitro assays and furthermore, the ADME-Tox profile of five advanced lead-compounds was evaluated. In vivo PK-studies including formulation optimization are performed in parallel. Based on our already established in vivo PoC, next steps include safety pharmacology in toxicological studies as well as efficacy studies in different animal models. We aim to finish the development of a clinical candidate by Q4/2020.
To further evaluate the compounds in the early clinical phases, aBACTER generally considers different exit strategies: regarding the development of the clinical candidate non-dilutive funding possibilities as well as combinations including investors are are being considered. In terms of early clinical development we plan to partner with midsize pharma, Venture Capital or private investors. As a possible final exit strategy including FDA-approval and market entry, aBACTER is aiming to be taken over by big pharma.
aBACTER is a pre-seed founder team located at TU Munich.
Prof. Dr. Stephan A. Sieber, CSO: his research comprises the investigation of novel antibacterial compounds and their targets funded by an ERC Consolidator Grant.
Three scientists combining expertise in chemistry, chemical biology and microbiology complete the team:
Dr. Franziska Mandl: project head, organic synthesis, microbiology, as well as project organization and budget planning.
Dr. Christian Fetzer: compound synthesis and microbiological characterization of compounds.
Dr. Mathias Hackl: assay development and coordination of CRO studies.
To complement our expertise we can rely on the knowledge of our industry/business development advisory board.
aBACTER is looking for further financing starting Q1/2020 to finish the development of a clinical candidate.
Searching forCommercial Partner, Funding, Collaboration